{
  "url": "https://struct.news/briefs/oil-treasuries-and-biotech-have-landed-in-the-same-market-cluster",
  "title": "Oil, Treasuries and biotech have landed in the same market cluster",
  "summary": "Twelve names were active on Aug. 17 across eight sectors, from USO and SHY to Apogee and BW LPG. Their usual relationships are close to nonexistent.",
  "published_at": "2026-08-17T23:47:03.355743+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": null,
    "ticker": null,
    "cik": null,
    "sector": null,
    "industry": null
  },
  "source_filing": null,
  "comparison_filing": null,
  "reported_figures": [
    {
      "group": "A cross-sector market cluster",
      "label": "Recent correlation",
      "value": 0.7892,
      "display": "0.79",
      "unit": "number",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Broad-market moves removed",
        "as_of": "2026-08-17"
      }
    },
    {
      "group": "A cross-sector market cluster",
      "label": "Usual correlation",
      "value": -0.0148,
      "display": "-0.01",
      "unit": "number",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Broad-market moves removed",
        "as_of": "2026-08-17"
      }
    },
    {
      "group": "A cross-sector market cluster",
      "label": "Above normal",
      "value": 4.25,
      "display": "4.2σ",
      "unit": "sigma",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Broad-market moves removed",
        "as_of": "2026-08-17"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "Zumilokibart spending increased as the APEX Phase 2 trial generated higher clinical-trial costs.",
      "importance": "medium",
      "evidence": "Research and development expense related to the zumilokibart program increased by $3.6 million in the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily driven by an increase in clinical trial-related expenses associated with our APEX Phase 2 clinical trial.",
      "source_date": "2026-08-10"
    },
    {
      "type": "product_pipeline",
      "statement": "Zumilokibart-related R&D rose as APEX Phase 2 clinical trial expenses increased.",
      "importance": "medium",
      "evidence": "Research and development expense related to the zumilokibart program increased by $3.6 million in the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily driven by an increase in clinical trial-related expenses associated with our APEX Phase 2 clinical trial.",
      "source_date": "2026-08-10"
    },
    {
      "type": "product_pipeline",
      "statement": "APG333/APG273 research expense declined as preclinical and clinical-trial expenses fell over the six-month comparison.",
      "importance": "medium",
      "evidence": "Research and development expense related to the APG333/APG273 program decreased by $3.0 million in the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to a reduction in preclinical research and development expenses and clinical trial related expenses.",
      "source_date": "2026-08-10"
    },
    {
      "type": "demand",
      "statement": "Construction-materials revenue benefited from pricing and acquisitions, but asphalt volumes were lower after adverse weather.",
      "importance": "medium",
      "evidence": "For construction materials, revenues increased slightly primarily due to higher pricing and the contribution from recent acquisitions, partially offset by lower volumes in our asphalt business, which was impacted by adverse weather.",
      "source_date": "2026-08-05"
    }
  ],
  "related_tickers": [
    "ACA",
    "APGE",
    "BWLP",
    "CRNX",
    "DBRG",
    "FORTY",
    "HYG",
    "JNK",
    "LXP",
    "SHY",
    "TECH",
    "USO"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}